Last 171.50 INR
Change Today -3.55 / -2.03%
Volume 182.0K
JOL On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

jubilant life sciences ltd (JOL) Snapshot

Open
175.80
Previous Close
175.05
Day High
176.65
Day Low
168.00
52 Week High
06/13/14 - 222.00
52 Week Low
08/28/13 - 65.10
Market Cap
27.3B
Average Volume 10 Days
256.6K
EPS TTM
6.85
Shares Outstanding
159.3M
EX-Date
08/21/14
P/E TM
25.0x
Dividend
3.00
Dividend Yield
1.75%
Current Stock Chart for JUBILANT LIFE SCIENCES LTD (JOL)

Related News

No related news articles were found.

jubilant life sciences ltd (JOL) Related Businessweek News

No Related Businessweek News Found

jubilant life sciences ltd (JOL) Details

Jubilant Life Sciences Limited, an integrated pharmaceutical and life sciences company, manufactures and supplies pharmaceutical and life sciences products and services worldwide. The company provides active pharmaceutical ingredients (APIs) for cardiovascular system (CVS) and central nervous system (CNS), as well as anti-infective and anti-ulcerants. Its APIs include solid dosage formulations for CVS, CNS, and anti-allergy categories; radiopharmaceuticals for the diagnosis, treatment, and monitoring of diseases; and allergy therapy products, including allergenic extracts and mixes, and skin test devices. The company also offers life sciences ingredients, such as pyridine and picoline; fine chemicals; crop science chemicals; nutrition products, including niacinamide, niacin (vitamin B3), and choline chloride; animal nutrition products in the category of vitamin and mineral premixes, betaine, acidifiers, toxin binders, growth promoters, and emulsifiers; acetyl products, which include acetic acid, monochloro acetic acid, acetic anhydride, ethyl acetate, and sodium mono chlor acetate; and specialty gases, such as liquid carbon dioxide and ethylene oxide mixtures. In addition, it provides contract manufacturing services in manufacturing sterile injectables, and solid and semi solid dosage forms; drug discovery services in bioinformatics, chemoinformatics, and crystallography structure directed molecular design and information technology; pre clinical services, such as medicinal chemistry, analytical chemistry, custom synthesis, library design, and clinical development and market launch services; and conducts integrated drug discovery and development programs on oncology, metabolic disorders, pain, and inflammation. The company was formerly known as Jubilant Organosys Limited and changed its name to Jubilant Life Sciences Limited in 2010. Jubilant Life Sciences Limited was incorporated in 1978 and is based in Noida, India.

6,200 Employees
Last Reported Date: 08/5/14
Founded in 1978

jubilant life sciences ltd (JOL) Top Compensated Officers

Vice President of Legal
Total Annual Compensation: --
Compensation as of Fiscal Year 2012.

jubilant life sciences ltd (JOL) Key Developments

Jubilant Life Sciences Limited Reports Unaudited Standalone and Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Provides Capex Guidance for the Full Year of Fiscal 2015

Jubilant Life Sciences Limited reported unaudited standalone earnings results for the first quarter ended June 30, 2014. For the quarter on standalone basis, the company reported net sales/income from operations of INR 10,260.1 million against INR 8,125.8 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 933.0 million against INR 772.1 million a year ago. Profit from ordinary activities before tax was INR 1,907.7 million against loss from ordinary activities before tax of INR 1,016.5 million a year ago. Net profit for the period was INR 2,037.2 million against net loss for the period of INR 1,058.8 million a year ago. Basic and diluted earnings per share were INR 12.79 against basic and diluted loss per share of INR 6.65 a year ago. For the quarter on consolidated basis, the company reported net sales/income from operations of INR 14,605.3 million against INR 13,180.4 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 724.6 million against INR 1,696.8 million a year ago. Loss from ordinary activities before tax was INR 199.5 million against INR 158.6 million a year ago. Net profit for the period was INR 93.8 million against net loss for the period of INR 472.9 million a year ago. Basic and diluted earnings per share were INR 0.30 against basic and diluted loss per share of INR 3.30 a year ago. Reported EBITDA stood at INR 1,500 million, resulting in a margin of 10.2%. During the quarter, the company spent about INR 450 million on capex. As of June 30, 2014, the company’s net debt stood at INR 39,170 million compared to INR 38,890 million a year ago. Taking into account the foreign currency fluctuations, the net debt stood at INR 39,170 million. Reported net profit after tax and minority interest was of INR 50 million compared to loss of INR 530 million a year ago. Normalized net profit after tax was INR 230 million compared to INR 590 million a year ago. For the full year, capex is to be about INR 3,000 million.

Jubilant Life Sciences Limited to Report Q1, 2015 Results on Aug 05, 2014

Jubilant Life Sciences Limited announced that they will report Q1, 2015 results on Aug 05, 2014

Jubilant Life Sciences Limited, Q1 2015 Earnings Call, Aug 05, 2014

Jubilant Life Sciences Limited, Q1 2015 Earnings Call, Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JOL:IN 171.50 INR -3.55

JOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dishman Pharmaceuticals & Chemicals Ltd 145.80 INR 0.00
Impax Laboratories Inc $24.43 USD -0.02
Piramal Enterprises Ltd 716.60 INR 0.00
Shasun Pharmaceuticals Ltd 193.10 INR 0.00
Torrent Pharmaceuticals Ltd 783.50 INR 0.00
View Industry Companies
 

Industry Analysis

JOL

Industry Average

Valuation JOL Industry Range
Price/Earnings 16.5x
Price/Sales 0.5x
Price/Book 1.0x
Price/Cash Flow 6.1x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUBILANT LIFE SCIENCES LTD, please visit www.jubl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.